Immunome Announces Pricing of Public Offering of Common Stock

Rhea-AI Summary

Immunome, Inc. (IMNM) announces the pricing of an underwritten public offering of 10,000,000 shares of its common stock at $20.00 per share, expecting to raise $200.0 million. The offering includes a 30-day option for additional shares. The offering is set to close on February 16, 2024, with J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities as joint book-running managers.

Financial Analyst

The announcement of Immunome's public offering of 10 million shares at $20.00 per share, with potential gross proceeds of $200 million, is a significant financial event. This capital raise can be a strategic move to fund research and development, expand operations, or pay down debt. It's crucial to assess the offering's pricing in relation to the current market price of Immunome's stock. If the offering price is at a discount, it might indicate a potential dilution effect, but it could also suggest a strategy to attract investors quickly. The market will react based on how this price compares to recent trading levels and the perceived value of the investment.

Furthermore, the underwriters' option to purchase additional shares could lead to further dilution but also provides a buffer for additional capital if the market demand is high. The involvement of reputable financial institutions as joint book-running managers and lead manager indicates a level of confidence in the offering's success. However, it's imperative to monitor the stock's performance following the offering to understand the market's reception and the long-term impact on the company's financial health.

Market Research Analyst

In biotechnology, public offerings are a common method for companies to secure funding for expensive and lengthy research and development processes. The market's response to such offerings can be indicative of the confidence investors have in the company's pipeline and future prospects. Immunome's targeted cancer therapies are part of a highly competitive and innovative sector that requires substantial investment. The success of this offering could signal market belief in their potential to produce a first-in-class or best-in-class therapy.

It's also important to consider the timing of the offering in relation to industry trends and the company's development milestones. If Immunome is nearing significant clinical trial results or regulatory milestones, the offering could provide the necessary resources at a critical time. Conversely, if the industry is facing headwinds or if Immunome's pipeline is in earlier stages than competitors, the offering could reflect a need to secure long-term financial stability amidst uncertainty.

Legal Expert

The use of a shelf registration statement for this public offering is a strategic legal maneuver that allows Immunome to act quickly in capitalizing on favorable market conditions. This method is efficient, as it was already filed and automatically became effective upon filing, streamlining the process. The availability of the preliminary prospectus supplement and the final prospectus supplement on the SEC's website ensures transparency and compliance with securities law, which is crucial for investor confidence.

It's important to note that the language 'this press release shall not constitute an offer to sell or a solicitation of an offer to buy' is standard legal disclaimer to prevent any premature trading based on the announcement. The stipulation that no sale will occur in jurisdictions where it would be unlawful is also a standard protective measure for the company and underwriters against potential legal challenges.

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share. All of the shares are to be sold by Immunome.

The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. In addition, Immunome has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 16, 2024, subject to the satisfaction of customary closing conditions.

J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 13, 2024 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by email at Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; or Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including ADCs, radioligand therapies, immunotherapies, and small molecules. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

Forward-looking Statements

Statements contained in this press release regarding Immunome’s expectations regarding the offering are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Immunome’s expectations of market conditions and the satisfaction of customary closing conditions related to the public offering, and the expected closing of the offering and the anticipated use of proceeds therefrom. These forward-looking statements are based upon Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, Immunome’s expectations regarding market conditions, the satisfaction of customary closing conditions related to the offering, Immunome's ability to complete the offering, and risks and uncertainties inherent in Immunome’s business. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Immunome's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Immunome's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Immunome undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240213676331/en/

Investor Contact:

Max Rosett

Interim Chief Financial Officer and EVP, Operations

mrosett@immunome.com

Source: Immunome, Inc.

FAQ

How many shares are included in Immunome's underwritten public offering?

Immunome is offering 10,000,000 shares of its common stock.

What is the price per share in Immunome's public offering?

The price per share in Immunome's public offering is $20.00.

How much is Immunome expecting to raise from the public offering?

Immunome expects to raise $200.0 million from the public offering.

When is the expected closing date of Immunome's public offering?

The public offering is expected to close on February 16, 2024.

Who are the joint book-running managers for Immunome's public offering?

J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers for the offering.